07:13 AM EDT, 10/11/2026 (MT Newswires) -- Merck KGaA's (MRK.F) phase 2b/3 study reviewing remigromig in patients with diabetic macular edema met its primary endpoint, according to an Oct. 10 release. The Brunello trial found that patients who had the 0.5 milligram and 0.8 milligram dose of remigromig had non-inferiority in mean change from the best-corrected visual acuity baseline, compared with patients who were dosed monthly with 0.5 milligrams of ranibizumab. Additionally, the study found that remigromig was generally well tolerated. However, proliferative diabetic retinopathy-related adverse events were observed to occur more with remigromig, compared with ranibizumab.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.